Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma

類似資料

• Comment on “MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma”
  著者:: Voruz, Sophie, 等
  出版事項: (2018)
• Trametinib in Histiocytic Sarcoma with an Activating MAP2K1 (MEK1) Mutation
  著者:: Gounder, Mrinal M., 等
  出版事項: (2018)
• Efficacy of MEK Inhibition in Patients with Histiocytic Neoplasms
  著者:: Diamond, Eli L., 等
  出版事項: (2019)
• MEK inhibition with trametinib is a successful therapy in ganglioglioma
  著者:: Daniel, Eliza Baird, 等
  出版事項: (2020)
• Trametinib Induces the Stabilization of a Dual GNAQ p.Gly48Leu- and FGFR4 p.Cys172Gly-Mutated Uveal Melanoma. The Role of Molecular Modelling in Personalized Oncology
  著者:: Krebs, Fanny S., 等
  出版事項: (2020)